Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
This study will evaluate the efficacy of Irinotecan,Capecitabine and Avastin combination in patients with no response to previous treatment with 5-Fluorouracil,Leucovorin,Eloxatin and Avastin.
Metastatic Colorectal Cancer
DRUG: Capecitabine|DRUG: Bevacizumab|DRUG: Irinotecan
Objective Response Rate, up to 6 months
Time To Progression, 1 year|Toxicity profile, Toxicity assessment on each chemotherapy|Quality of life, Assessment every two cycles|Symptoms improvement, Assessment every two cycles|Overall Survival, 1 year
The aim of this phase II study is to evaluate the efficacy of the combination XELIRI/AVASTIN in patients with mCRC, who have progressed in first line treatment with FOLFOX/AVASTIN. For AVASTIN was selected the dosing schedule of the trials TREE 1 and 2 \[17\], where Avastin was combined with capecitabine and oxaliplatin in a three weeks schedule and with adaptation of the dose in the 7,5 mg/kg